Right now, doctors at select centers in the U.S. are accepting participants for a new clinical research study.
This study is for a new investigational oral drug for CAH that aims to treat the underlying disease, and reduce the steroid burden on patients.
Congenital adrenal hyperplasia (CAH) is a rare genetic disorder affecting the adrenal glands.
People with CAH have an impaired ability to produce cortisol, also known as “the stress hormone,” which has an effect on energy, blood pressure, and the body’s response to stress, illness and injury.
While chronic high dose steroids can effectively replace the body’s cortisol, they may cause a number of health challenges, including obesity, high blood pressure, osteoporosis and infertility.
If you qualify and choose to join the study, you will receive study-related:
If you are 18 years of age or older, and have been diagnosed with classic CAH, you may qualify to participate.
To see if you might qualify for the study, and to get connected with your local study center to discuss the study further, the next step is taking the pre-screening questionnaire.
Clinical studies (also called clinical trials) are used to learn about the safety and effectiveness of possible new medications, medical devices, and medical procedures. Although there are many types of clinical trials, all must conform to strict rules set by the U.S. Food and Drug Administration (FDA). These rules help protect the rights and safety of those who volunteer to take part in clinical trials.
The study is being sponsored by Spruce Biosciences, a biopharmaceutical company based in San Francisco.
The first visit is a screening visit to help determine if the study is a good fit for you.
If you and the study are a fit, you will enter a two-week treatment period, made up of 3 visits to the study center.
Your final visit will be a follow up, scheduled around a month after your last treatment visit.
See if you might qualify for the study, and to get connected with the study center in your area to learn more.